Euro Area consumer confidence has improved for four straight months and inflation expectations are easing, which suggests households may feel more comfortable spending again. That kind of backdrop can support companies that are already expected to grow earnings strongly and maintain solid balance sheets. This article looks at three stocks from the Healthy high growth potential screener that fit that profile and explains what makes each worth a closer look now.

The three stocks featured below are just a small sample of this theme, and the full screen surfaced 1,546 more companies with similarly compelling growth profiles and financial footing that are not covered here. To go straight to the source, use the Healthy high growth potential screener to identify, filter, and analyze the ideas that best fit your own conviction.

Amylyx Pharmaceuticals (AMLX)

Amylyx Pharmaceuticals is a clinical-stage company focused on drug candidates for neurodegenerative and rare endocrine conditions that tie directly into the Healthy high growth potential theme through its late-stage pipeline, especially avexitide and AMX0035. The company is not yet generating commercial revenue, so the investment case revolves around the potential of these programs rather than current sales. Amylyx has a market cap of about US$4.3b, which reflects investor focus on its future earnings potential rather than its present income statement.

Amylyx Pharmaceuticals is worth a closer look if you want exposure to a late-stage biotech where the growth story is anchored in clear clinical milestones. Positive Phase 3 LUCIDITY data for avexitide and plans for an NDA submission by the end of 2026 point to a possible first commercial product in a setting with no existing approved therapies. At the same time, the company remains pre-commercial, carries ongoing losses and has raised fresh equity to fund launch and R&D, so execution, dilution, and regulatory risk are very real. The broader GLP-1 antagonist and neurodegeneration pipeline, along with analysts’ expectations for strong future earnings expansion, is what makes the story interesting.

Amylyx Pharmaceuticals sits at the point where late stage potential and real execution risk are starting to collide. Get the full story with the 2 key rewards and 4 important warning signs (2 are major!)

Rocket Lab (RKLB)

Rocket Lab is a space company that designs and launches small and medium rockets, while also supplying satellites and key components to commercial and government customers, which ties directly into the Healthy high growth potential theme through its Electron launches and Neutron program that target growing demand for satellite constellations. The business currently generates most of its revenue from Space Systems at about US$544 million, with Launch Services contributing roughly US$225 million, so the higher profile rockets are only part of a broader space infrastructure platform. Rocket Lab has a market cap of around US$43.4 billion, which reflects investor focus on the long term earnings potential of this combined launch and space systems model.

Rocket Lab appeals if you want exposure to the space economy where growth expectations are backed by real hardware, a rising launch cadence and a sizeable contracted backlog around US$2.3 to US$2.4 billion. The Electron rocket and upcoming Neutron vehicle are central to that story, with new Space Force contracts and the proposed US$8 billion Iridium acquisition adding recurring services to complement launch revenue. At the same time, the company remains unprofitable, has relied on external borrowing and equity dilution, and faces execution risk around Neutron’s first flights and integrating Iridium. For investors willing to accept that risk, Rocket Lab offers a focused way to participate in the next phase of satellite and space infrastructure growth without needing to pick individual constellations.

Rocket Lab’s launch growth story is only half the picture. The real question is how its contracts, balance sheet and Neutron ambitions fit together. Get the full context in the analysis report for Rocket Lab.

Iovance Biotherapeutics (IOVA)

Iovance Biotherapeutics is a commercial stage biotech company focused on autologous TIL cell therapies for hard to treat solid tumors, which is exactly what ties it into the Healthy high growth potential theme. Its business is centered on Amtagvi, an individualized T cell therapy for advanced melanoma, alongside the broader TIL pipeline. Together these generated about US$325 million in revenue, almost entirely from the United States. Iovance Biotherapeutics has a market cap of roughly US$3.8b.

Iovance Biotherapeutics is drawing fresh attention because Amtagvi is already generating product revenue and margins while the TIL pipeline is still working through new cancer indications that could change the company’s profile. Q2 2026 revenue of about US$99 million, a 56% gross margin and guidance of US$350 million to US$370 million for 2026 illustrate the current pace of commercial scaling. This underpins the strong earnings growth forecasts that brought it into this screener. On the other hand, the company remains loss making, relies on external funding and has diluted shareholders, so execution on commercialization and regulatory milestones is critical. Recent analyst target upgrades after Q2 results reflect how sentiment may be shifting as Amtagvi demand, treatment center coverage and international approvals develop. However, there is more to consider before deciding how this growth and risk profile fits your portfolio.

Iovance Biotherapeutics already has real Amtagvi revenue and a live TIL pipeline, yet the full earnings story still feels incomplete. Walk through the analyst forecasts in the analyst forecasts for Iovance Biotherapeutics to see what might be hiding in plain sight.

Seeking Fresh Alternatives Before They Fly

Fresh breakout stories often move fast, and the best entry points can be gone before the crowd even looks. Scan these under the radar ideas while it matters and consider acting promptly.

• Spot resilient compounders that may hold up when volatility bites by scanning the 75 resilient stocks with low risk scores while the crowd is still fixated on headlines.
• Explore structural demand for power and grid upgrades by checking the curated 39 power grid technology and infrastructure stocks before capital targets the same theme and entry prices move away.
• Review companies involved in the AI infrastructure build out by using the focused 55 AI infrastructure stocks while many investors are still concentrating on the obvious mega caps.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.